Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €30.77 EUR
Change Today -1.14 / -3.58%
Volume 240.0
AB3A On Other Exchanges
Symbol
Exchange
Frankfurt
As of 10:23 AM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Sandesh Mahatme LL.M.

Chief Financial Officer, Chief Accounting Officer and Senior Vice President,Sarepta Therapeutics, Inc.
AgeTotal Calculated CompensationThis person is connected to 12 board members in 2 different organizations across 3 different industries.

See Board Relationships
50$2,183,029
As of Fiscal Year 2014

Background*

Mr. Sandesh Mahatme, also known as Sandy, LL.M., has been the Chief Financial Officer and Senior Vice President of Sarepta Therapeutics, Inc. since November 5, 2012 and Chief Accounting Officer since October 4, 2013. Prior to Sarepta, Mr. Mahatme served in various roles including Senior Vice President of Corporate Development, Corporate Treasurer and Senior Vice President of Tax at Celgene Corporation since 2006. At Celgene, he was instrumental in building Celgene's ...

Read Full Background

Corporate Headquarters*

215 First Street
Cambridge, Massachusetts 02142

United States

Phone: 617-274-4000
Fax: --

Board Members Memberships*

2014-Present
Director and Chairman of Audit Committee
2015-Present
Director

Education*

Master's Degree
Cornell University School of Law
Master's Degree
New York University School Of Law

Other Affiliations*

Annual Compensation*

Salary$443,722
Total Annual Compensation$443,722

Stock Options*

All Other Compensation$65,637
Exercisable Options155,520
Unexercisable Options234,480
Total Number of Options449,906

Total Compensation*

Total Annual Cash Compensation$660,224
Total Short Term Compensation$443,722
Other Long Term Compensation$65,637
Total Calculated Compensation$2,183,029
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AB3A:GR €30.77 EUR -1.14

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ali Mortazavi Chief Executive (leave of absence) and Director
Silence Therapeutics plc
200.0K GBP
Mark W. Schwartz Ph.D.Chief Executive Officer, President, Director and Member of Ad Hoc (Strategy, Pricing, Etc) Committee
Galena Biopharma, Inc.
$707.1K
Mark Joseph Murray Ph.D.Chief Executive Officer, President and Director
Arbutus Biopharma Corporation
$580.0K
Paul C. Grint M.D.Chief Executive Officer, President and Director
Regulus Therapeutics Inc.
--
Douglas M. Fambrough III, Ph.D.Co-Founder, Chief Executive Officer, President and Director
Dicerna Pharmaceuticals, Inc.
$430.0K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAREPTA THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.